SafeCue Industry Pulse 2026
Early Observations on ICSR Narrative Consistency and Inspection Defensibility
ICSR narratives play a critical role in pharmacovigilance by providing the clinical context necessary to understand patient safety events and the reasoning behind a company’s safety assessment. While structured case data supports regulatory reporting requirements, narratives often provide the clinical story that allows reviewers, auditors, and inspectors to interpret how safety conclusions were reached.
At SafeCue Solutions, we recently conducted a small exploratory survey among pharmacovigilance professionals to better understand perspectives on ICSR narrative quality, consistency, and inspection defensibility across safety workflows.
While the number of responses was limited, the consistency of themes across respondents was notable.
Key Observations
Several common themes emerged from the survey responses:
Narrative variability across similar cases
Respondents frequently reported differences in narrative structure and causality language across cases with similar clinical scenarios. Variability may arise when multiple writers contribute to narrative development or when follow-up information is incorporated over time.
Quality control often focuses on technical completeness
Many respondents indicated that QC processes emphasize verifying required narrative components, chronology, and template adherence. While these checks are essential for compliance, the clarity of clinical reasoning may depend heavily on the initial narrative development process.
Workflow transitions introduce narrative variation
Participants noted that narrative variability often emerges as cases move between different stages of the pharmacovigilance workflow, including narrative writing, QC review, and medical assessment. Each transition can introduce subtle differences in how the clinical story is framed.
Clinical reasoning supports inspection-defensible narratives
Across respondents, one theme was consistent: narratives that clearly explain the clinical reasoning behind a safety assessment are more likely to withstand regulatory scrutiny. A well-constructed narrative should allow the reader to understand the case history, relevant clinical context, and how the causality conclusion was reached.
Why Narrative Consistency Matters
Narratives are often one of the first components reviewed during regulatory inspections or internal audits. While compliance with required narrative elements is essential, inspection defensibility often depends on how clearly the clinical story is documented.
Maintaining narrative consistency across cases requires alignment across multiple stages of the safety workflow, including narrative development, quality review, and medical assessment.
Looking Ahead
This exploratory survey represents an early step toward understanding how pharmacovigilance teams approach narrative consistency and defensibility in practice. Future analysis with a larger respondent population may provide additional insight into how organizations can strengthen narrative consistency and the documentation of clinical reasoning across safety workflows.
SafeCue Solutions provides independent pharmacovigilance quality and defensibility oversight for biotech and CRO safety teams.
